157 related articles for article (PubMed ID: 36046208)
21. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI
Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683
[TBL] [Abstract][Full Text] [Related]
22. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Cohen AT; Spiro TE; Spyropoulos AC; Desanctis YH; Homering M; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Tapson VF; Burton P;
J Thromb Haemost; 2014 Apr; 12(4):479-87. PubMed ID: 24460645
[TBL] [Abstract][Full Text] [Related]
23. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
[TBL] [Abstract][Full Text] [Related]
24. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Spyropoulos AC; Lipardi C; Xu J; Peluso C; Spiro TE; De Sanctis Y; Barnathan ES; Raskob GE
TH Open; 2020 Jan; 4(1):e59-e65. PubMed ID: 32190813
[TBL] [Abstract][Full Text] [Related]
25. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Turpie AG; Wildgoose P; Yusen RD
J Thromb Thrombolysis; 2006 Aug; 22(1):31-8. PubMed ID: 16786230
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
28. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
Liew AY; Piran S; Eikelboom JW; Douketis JD
J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
[TBL] [Abstract][Full Text] [Related]
29. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
[TBL] [Abstract][Full Text] [Related]
30. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Imberti D; Pomero F; Mastroiacovo D
Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
[TBL] [Abstract][Full Text] [Related]
32. Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial.
Ren Y; Cao SL; Li Z; Luo T; Feng B; Weng XS
Chin Med J (Engl); 2021 Jan; 134(2):164-172. PubMed ID: 33410616
[TBL] [Abstract][Full Text] [Related]
33. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
[TBL] [Abstract][Full Text] [Related]
34. Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE.
Yamada N; Fu W; Shi Z; Park KH; Kim HS; Dai X; Lensing AW; Pap AF; Kohno T; Tajima T; Watakabe T; Mitsumori T
Thromb J; 2024 Jun; 22(1):48. PubMed ID: 38844941
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea.
Kim HA; Lee JY; Park SH; Kang J; Choi KS; Rhie SJ
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):507-514. PubMed ID: 30848013
[TBL] [Abstract][Full Text] [Related]
36. Pentasaccharides for the prevention of venous thromboembolism.
Dong K; Song Y; Li X; Ding J; Gao Z; Lu D; Zhu Y
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005134. PubMed ID: 27797404
[TBL] [Abstract][Full Text] [Related]
37. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism].
Kaymaz C
Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):1-7. PubMed ID: 28947723
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients.
Xie J; Jiang M; Lin Y; Deng H; Xie X; Li L
Thromb Haemost; 2019 Sep; 119(9):1517-1526. PubMed ID: 31365943
[TBL] [Abstract][Full Text] [Related]
39. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
40. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis.
Bajaj NS; Vaduganathan M; Qamar A; Gupta K; Gupta A; Golwala H; Butler J; Goldhaber SZ; Mehra MR
PLoS Med; 2019 Apr; 16(4):e1002797. PubMed ID: 31034476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
